Azam T, Zhang H, Zhou F, Wang X. Recent advances on drug development and emerging therapeutic agents through targeting cellular homeostasis for ageing and cardiovascular disease. Front Aging. 2022;3:888190. https://doi.org/10.3389/fragi.2022.888190.

Article  PubMed  PubMed Central  Google Scholar 

Fang X, Ardehali H, Min J, Wang F. The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease. Nat Rev Cardiol. 2023;20(1):7–23. https://doi.org/10.1038/s41569-022-00735-4.

Article  PubMed  Google Scholar 

Friedmann Angeli JP, Schneider M, Proneth B, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol. 2014;16(12):1180–91. https://doi.org/10.1038/ncb3064.

Article  CAS  PubMed  Google Scholar 

Yagoda N, von Rechenberg M, Zaganjor E, et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature. 2007;447(7146):864–8. https://doi.org/10.1038/nature05859.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dolma S, Lessnick SL, Hahn WC, Stockwell BR. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell. 2003;3(3):285–96. https://doi.org/10.1016/s1535-6108(03)00050-3.

Article  CAS  PubMed  Google Scholar 

Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–72. https://doi.org/10.1016/j.cell.2012.03.042.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Galluzzi L, Vitale I, Aaronson SA, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018;25(3):486–541. https://doi.org/10.1038/s41418-017-0012-4.

Article  PubMed  PubMed Central  Google Scholar 

Park TJ, Park JH, Lee GS, et al. Quantitative proteomic analyses reveal that GPX4 downregulation during myocardial infarction contributes to ferroptosis in cardiomyocytes. Cell Death Dis. 2019;10(11):835. https://doi.org/10.1038/s41419-019-2061-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qin Y, Qiao Y, Wang D, Tang C, Yan G. Ferritinophagy and ferroptosis in cardiovascular disease: mechanisms and potential applications. Biomed Pharmacother. 2021;141:111872. https://doi.org/10.1016/j.biopha.2021.111872.

Wang R, Wang M, Zhou J, et al. Saponins in Chinese herbal medicine exerts protection in myocardial ischemia-reperfusion injury: possible mechanism and target analysis. Front Pharmacol. 2020;11:570867. https://doi.org/10.3389/fphar.2020.570867.

Dong L, Shen Z, Chi H, et al. Research progress of Chinese medicine in the treatment of myocardial ischemia-reperfusion injury. Am J Chin Med. 2023;51(1):1–17. https://doi.org/10.1142/s0192415x23500015.

Article  CAS  PubMed  Google Scholar 

Zhang Y, Xin L, Xiang M, et al. The molecular mechanisms of ferroptosis and its role in cardiovascular disease. Biomed Pharmacother. 2022;145:112423. https://doi.org/10.1016/j.biopha.2021.112423.

Chen Z, Yan Y, Qi C, et al. The role of ferroptosis in cardiovascular disease and its therapeutic significance. Front Cardiovasc Med. 2021;8:733229. https://doi.org/10.3389/fcvm.2021.733229.

Li D, Pi W, Sun Z, Liu X, Jiang J. Ferroptosis and its role in cardiomyopathy. Biomed Pharmacother. 2022;153:113279. https://doi.org/10.1016/j.biopha.2022.113279.

Del Re DP, Amgalan D, Linkermann A, Liu Q, Kitsis RN. Fundamental mechanisms of regulated cell death and implications for heart disease. Physiol Rev. 2019;99(4):1765–817. https://doi.org/10.1152/physrev.00022.2018.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rochette L, Gudjoncik A, Guenancia C, et al. The iron-regulatory hormone hepcidin: a possible therapeutic target? Pharmacol Ther. 2015;146:35–52. https://doi.org/10.1016/j.pharmthera.2014.09.004.

Article  CAS  PubMed  Google Scholar 

Ge XH, Wang Q, Qian ZM, et al. The iron regulatory hormone hepcidin reduces ferroportin 1 content and iron release in H9C2 cardiomyocytes. J Nutr Biochem. 2009;20(11):860–5. https://doi.org/10.1016/j.jnutbio.2008.07.014.

Article  CAS  PubMed  Google Scholar 

Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090–3. https://doi.org/10.1126/science.1104742.

Article  CAS  PubMed  Google Scholar 

Camaschella C, Nai A, Silvestri L. Iron metabolism and iron disorders revisited in the hepcidin era. Haematologica. 2020;105(2):260–72. https://doi.org/10.3324/haematol.2019.232124.

Article  CAS  PubMed  PubMed Central  Google Scholar 

He YJ, Liu XY, Xing L, et al. Fenton reaction-independent ferroptosis therapy via glutathione and iron redox couple sequentially triggered lipid peroxide generator. Biomaterials. 2020;241:119911. https://doi.org/10.1016/j.biomaterials.2020.119911.

Kajarabille N, Latunde-Dada GO. Programmed cell-death by ferroptosis: antioxidants as mitigators. Int J Mol Sci. 2019;20(19). https://doi.org/10.3390/ijms20194968.

Zhou B, Liu J, Kang R, et al. Ferroptosis is a type of autophagy-dependent cell death. Semin Cancer Biol. 2020;66:89–100. https://doi.org/10.1016/j.semcancer.2019.03.002.

Article  CAS  PubMed  Google Scholar 

Baba Y, Higa JK, Shimada BK, et al. Protective effects of the mechanistic target of rapamycin against excess iron and ferroptosis in cardiomyocytes. Am J Physiol Heart Circ Physiol. 2018;314(3):H659-h68. https://doi.org/10.1152/ajpheart.00452.2017.

Article  CAS  PubMed  Google Scholar 

Guan P, Wang N. Mammalian target of rapamycin coordinates iron metabolism with iron-sulfur cluster assembly enzyme and tristetraprolin. Nutrition. 2014;30(9):968–74. https://doi.org/10.1016/j.nut.2013.12.016.

Article  CAS  PubMed  Google Scholar 

Aoyagi T, Kusakari Y, Xiao CY, et al. Cardiac mTOR protects the heart against ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2012;303(1):H75-85. https://doi.org/10.1152/ajpheart.00241.2012.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bayeva M, Khechaduri A, Puig S, et al. mTOR regulates cellular iron homeostasis through tristetraprolin. Cell Metab. 2012;16(5):645–57. https://doi.org/10.1016/j.cmet.2012.10.001.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gaschler MM, Stockwell BR. Lipid peroxidation in cell death. Biochem Biophys Res Commun. 2017;482(3):419–25. https://doi.org/10.1016/j.bbrc.2016.10.086.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stockwell BR, Friedmann Angeli JP, Bayir H, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171(2):273–85. https://doi.org/10.1016/j.cell.2017.09.021.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Su LJ, Zhang JH, Gomez H, et al. Reactive oxygen species-induced lipid peroxidation in apoptosis, autophagy, and ferroptosis. Oxid Med Cell Longev. 2019;2019:5080843. https://doi.org/10.1155/2019/5080843.

Stoyanovsky DA, Tyurina YY, Shrivastava I, et al. Iron catalysis of lipid peroxidation in ferroptosis: regulated enzymatic or random free radical reaction? Free Radic Biol Med. 2019;133:153–61. https://doi.org/10.1016/j.freeradbiomed.2018.09.008.

Article  CAS  PubMed  Google Scholar 

Conrad M, Pratt DA. The chemical basis of ferroptosis. Nat Chem Biol. 2019;15(12):1137–47. https://doi.org/10.1038/s41589-019-0408-1.

Article  CAS  PubMed  Google Scholar 

Lin Z, Liu J, Kang R, Yang M, Tang D. Lipid metabolism in ferroptosis. Adv Biol (Weinh). 2021;5(8):e2100396. https://doi.org/10.1002/adbi.202100396.

Cui C, Yang F, Li Q. Post-translational modification of GPX4 is a promising target for treating ferroptosis-related diseases. Front Mol Biosci. 2022;9:901565. https://doi.org/10.3389/fmolb.2022.901565.

Naoe S, Tsugawa H, Takahashi M, Ikeda K, Arita M. Characterization of lipid profiles after dietary intake of polyunsaturated fatty acids using integrated untargeted and targeted lipidomics. Metabolites. 2019;9(10). https://doi.org/10.3390/metabo9100241.

Kagan VE, Mao G, Qu F, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol. 2017;13(1):81–90. https://doi.org/10.1038/nchembio.2238.

Article  CAS  PubMed  Google Scholar 

Xu Y, Li X, Cheng Y, Yang M, Wang R. Inhibition of ACSL4 attenuates ferroptotic damage after pulmonary ischemia-reperfusion. Faseb j. 2020;34(12):16262–75. https://doi.org/10.1096/fj.202001758R.

Article  CAS  PubMed  Google Scholar 

Orafaie A, Mousavian M, Orafai H, Sadeghian H. An overview of lipoxygenase inhibitors with approach of in vivo studies. Prostaglandins Other Lipid Mediat. 2020;148:106411. https://doi.org/10.1016/j.prostaglandins.2020.106411.

Shah R, Shchepinov MS, Pratt DA. Resolving the role of lipoxygenases in the initiation and execution of ferroptosis. ACS Cent Sci. 2018;4(3):387–96. https://doi.org/10.1021/acscentsci.7b00589.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Doll S, Proneth B, Tyurina YY, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2017;13(1):91–8. https://doi.org/10.1038/nchembio.2239.

Article  CAS  PubMed  Google Scholar 

Feng J, Lu PZ, Zhu GZ, et al. ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma. Acta Pharmacol Sin. 2021;42(1):160–70. https://doi.org/10.1038/s41401-020-0439-x.

Article  CAS  PubMed  Google Scholar 

Yuan H, Li X, Zhang X, Kang R, Tang D. Identification of ACSL4 as a biomarker and contributor of ferroptosis. Biochem Biophys Res Commun. 2016;478(3):1338–43. https://doi.org/10.1016/j.bbrc.2016.08.124.

Article  CAS  PubMed